Understanding within-patient Mycobacterium tuberculosis genetic diversity to prevent drug-resistance (360G-Wellcome-203583_Z_16_Z)
Tuberculosis, caused by Mycobacterium tuberculosis (M.tb), is a major public health problem. Drug-resistant tuberculosis (DR-TB) cases are increasing, creating a significant barrier to disease control. DR-TB is difficult to diagnose and treatment often takes years. M.tb was traditionally thought to be genetically homogenous within the human host, but deep whole genome sequencing (WGS) data have revealed evidence of within-host genetic heterogeneity (GH), particularly in drug-resistance genes. Changing GH patterns over time can cause acquired drug-resistance (ADR). However, how and where in the host GH arises, or how important it is for ADR is not known. I hypothesise that GH represents isolated M.tb subpopulations in separate lung lesions within a patient, and that development of GH is related to local pathology or drug penetration. I will investigate this by WGS of M.tb extracted from resected human lung tissue, and comparing GH to pathology type and local drug concentrations. To evaluate whether GH causes ADR, I will follow patients with newly diagnosed MDR-TB and perform WGS of sequential sputum samples over 6 months for WGS. I will evaluate if ADR is related to baseline GH. Understanding the role of GH in ADR could help develop prevention strategies.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 380125 |
Applicant Surname | Nimmo |
Approval Committee | International Interview Committee |
Award Date | 2016-06-29T00:00:00+00:00 |
Financial Year | 2015/16 |
Grant Programme: Title | Research Training Fellowship |
Internal ID | 203583/Z/16/Z |
Lead Applicant | Dr Camus Nimmo |
Partnership Value | 380125 |
Planned Dates: End Date | 2020-10-05T00:00:00+00:00 |
Planned Dates: Start Date | 2017-04-05T00:00:00+00:00 |
Recipient Org: Country | United Kingdom |
Region | Greater London |
Sponsor(s) | Dr Alexander Pym, Prof Judith Breuer |